KALA Kala Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KALA

Price (delayed)

$5.71

Market cap

$15.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$22.78

Enterprise value

-$4.6M

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery ...

Highlights
The EPS has surged by 59% year-on-year
Kala Pharmaceuticals's net income has increased by 42% YoY
KALA's debt is down by 15% YoY but it is up by 7% QoQ
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
The revenue has shrunk by 100% QoQ and by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://kalarx.com
Peers: OGN

Key stats

What are the main financial stats of KALA
Market
Shares outstanding
2.69M
Market cap
$15.38M
Enterprise value
-$4.6M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$40.49M
EBITDA
-$40.07M
Free cash flow
-$34.47M
Per share
EPS
-$22.78
Free cash flow per share
-$13.52
Book value per share
$4.41
Revenue per share
$0
TBVPS
$23.97
Balance sheet
Total assets
$61.12M
Total liabilities
$49.9M
Debt
$36.08M
Equity
$11.22M
Working capital
$47.6M
Liquidity
Debt to equity
3.22
Current ratio
5.62
Quick ratio
5.44
Net debt/EBITDA
0.5
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-64.8%
Return on equity
-260.9%
Return on invested capital
-118.2%
Return on capital employed
-79.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KALA stock price

How has the Kala Pharmaceuticals stock price performed over time
Intraday
-4.52%
1 week
-8.35%
1 month
-16.28%
1 year
1.06%
YTD
-85.03%
QTD
-35.84%

Financial performance

How have Kala Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.17M
Net income
-$46.42M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
The revenue has shrunk by 100% QoQ and by 100% YoY
KALA's operating income has soared by 67% YoY and by 9% QoQ
Kala Pharmaceuticals's net income has increased by 42% YoY

Growth

What is Kala Pharmaceuticals's growth rate over time

Valuation

What is Kala Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 59% year-on-year
The price to book (P/B) is 58% lower than the 5-year quarterly average of 3.2 and 36% lower than the last 4 quarters average of 2.1
Kala Pharmaceuticals's equity has decreased by 36% QoQ
The revenue has shrunk by 100% QoQ and by 100% YoY

Efficiency

How efficient is Kala Pharmaceuticals business performance
The ROIC fell by 26% YoY
The company's return on assets rose by 14% YoY

Dividends

What is KALA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KALA.

Financial health

How did Kala Pharmaceuticals financials performed over time
The total assets is 22% more than the total liabilities
KALA's current ratio has soared by 168% YoY but it is down by 15% QoQ
The company's total liabilities fell by 42% YoY
The debt to equity has soared by 107% YoY and by 68% from the previous quarter
Kala Pharmaceuticals's equity has decreased by 36% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.